Lannett Expand its Partnership with HEC to Include Biosimilar Fast-Acting Insulin
Shots:
- The companies collaborated to co-develop Insulin aspart while Lannett granted exclusive US commercialization rights of insulin aspart to HEC
- Lannett will fund the clinical development requirements and will manage the clinical & regulatory steps specific for the FDA’s approval while HEC continues to develop the product and related manufacturing infrastructure. Both companies will share the profits of the venture
- Insulin aspart is a short-acting (fast-acting) insulin typically taken just before eating- is used to treat adults with T1D & T2D
Ref: PRNewswire | Image: Lannett Company
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com